Antisoma shares plunge after latest cancer drug setback
Tuesday 01 February 2011
Antisoma suffered a blow last night after it revealed that a key acute leukaemia drug had failed in a final-stage clinical trial.
The biotech firm said it had also halted the development of another cancer treatment after early data from an ongoing penultimate-stage trial showed that the result was likely to be inconclusive.
The news triggered a sharp sell-off in Antisoma's shares, which closed at 2.2p, down more than 64 per cent. The decline leaves the firm valued at around £14m.
Glyn Edwards, Antisoma's chief executive, said the company had not seen a benefit with the AS1413 leukaemia treatment. "This is hugely disappointing for patients, investigators, investors and employees" he said. "We will now become smaller and focus on maximising the value of our other programmes."
Paul Cuddon at the Peel Hunt brokerage said the developments meant that "other than a £23m cash balance, which is continuing to decline, there are few assets left to value in the Antisoma pipeline".
He warned: "Other than 3.5p of cash, which we anticipate will fall to 2p, little value remains in Antisoma, and sadly we fail to see an ongoing future."
Samir Devani at Nomura Code Securities said the failure of the AS1413 final-stage trial was "not a huge surprise" as he had only assumed a 30 per cent chance of success.
The setback did, however, have a "major impact" on Antisoma's valuation, he added.
"We expect the company to go into cash-conserving mode and anticipate a significant restructuring in the near-term," he explained.
The latest setback comes less than a year after Antisoma's key lung cancer drug, ASA404, failed in March.
- 1 Michael Brown shooting: Police shoot and kill second young black man near Ferguson
- 2 James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – and warns Obama of more to come
- 3 ALS ice bucket challenge co-founder Corey Griffin drowns aged 27
- 4 Cilla Black defends Cliff Richard: 'I am positive that the allegations are without foundation'
- 5 James Foley 'beheading': Met police warn public watching murder video could be criminal offence
James Foley 'beheaded': PM cuts holiday short for emergency meeting on British response to latest Isis atrocity
Michael Brown shooting: Police shoot and kill second young black man near Ferguson
ALS ice bucket challenge co-founder Corey Griffin drowns aged 27
James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – and warns Obama of more to come
Iraq crisis: Islamic State's message to America - 'We will drown you all in blood'
Scottish independence: English people overwhelmingly want Scotland to stay in the UK
Isis threat: Cameron wants an alliance with Iran
Crisis? What crisis? A visiting US doctor gives the NHS a rave review
Ukip MEP calls for reintroduction of death penalty on fiftieth anniversary of last deaths
Russell Brand calls for Israel boycott: Comedian urges big businesses that 'facilitate the oppression of people in Gaza' to pull funding
Michael Brown shooting: Chaos erupts on the streets of Ferguson after autopsy shows teenager was shot six times – twice in the head
iJobs Money & Business
£450 - £600 per day: Harrington Starr: AIFMD Business Analyst / Consultant - I...
£450 - £600 per day: Harrington Starr: Business Analyst Solvency II SME (Pilla...
£350 - £365 per day: Orgtel: Manager, SAS, Data Warehouse, Banking, Bristol - ...
£500 per day: Harrington Starr: SQL DBA/Developer SQL, C#, VBA, Linux, SQL Se...